RxDoctor Payments Data

Mir Husain, MD

Infectious Disease · Austell, GANPI 1235234527

Payments from drug & device makers

$5,702in general payments, 2019–2025

Across 185 payments — averaging $30.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$2K
  • Viiv Healthcare Company$572
  • Gilead$499
  • Merck$469
  • AbbVie$409
  • Shionogi Inc$388
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$1,62028%
  • Travel & lodging$180%
  • Food & beverage$3,76966%
  • Education$2955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,702 in reported general payments places this provider in the 65th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$91,051
Medicare patients
224
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala92$378,559
OdefseyEmtricitab/Rilpiviri/Tenof Ala55$209,928
JulucaDolutegravir/Rilpivirine44$148,687
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf14$66,859
Daptomycin19$34,897
IsentressRaltegravir Potassium13$24,690
Ampicillin Sodium16$3,827
Doxycycline Hyclate32$1,107
CeftriaxoneCeftriaxone Sodium17$570
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$470
Ciprofloxacin Hcl13$257
Cephalexin19$224
Atorvastatin Calcium18$141
Tramadol Hcl11$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$499$378,55992 claims
Viiv Healthcare CompanyJuluca$572$148,68744 claims
Janssen Products, LPSymtuza$254$66,85914 claims
MerckIsentress$469$24,69013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →